Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: A phase I-II study

Annals of Oncology

Volumn 16, Issue 5, 2005, Pages 762-766

  Seium, Y ^a   Stupp, R ^b   Ruhstaller, T ^c   Gervaz, P ^a   Mentha, G ^a   Philippe, M ^a   Allal, A ^a   Trembleau, C ^a   Bauer, J ^b   Morant, R ^d   Roth, Arnaud D ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d Tumor Center ZeTuP   (Switzerland)

Author keywords

Colorectal cancer; Irinotecan; Oxaliplatin; Triplet regimen

Indexed keywords

ATROPINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; METOCLOPRAMIDE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; ILEUS; KIDNEY FUNCTION; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYCOSIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; RECURRENCE RISK; SEPTICEMIA; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 20044370825     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi154     Document Type: Article

References (19)

1. Moertel CG. Drug therapy: Chemotherapy for colorectal cancer. Cancer Res 1994; 54: 2390-2397.
2. Thirion P, Wolmark N, Haddad E et al. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol 1999; 10: 1317-1320.
3. Andre T, Louvet C, Raymond E et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251-1253.
4. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-98.
5. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
6. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
7. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
8. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
9. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
10. Gill S, Thomas RR, Goldberg RM. Review article: colorectal cancer chemotherapy. Aliment Pharmacol Ther 2003; 18: 683-692.
11. Tanaka K, Adam R, Shimada H et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963-969.
12. Falcone A, Masi G, Allegrini G et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006-4014.
13. Calvo E, Cortes J, Rodriguez J et al. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002; 2: 104-110.
14. Hofheinz R, Hartung G, Samel S et al. Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer-a phase II study. Anticancer Drugs 2002; 13: 999-1004.
15. Stickel F, Jungert B, Brueckl V et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 2003; 14: 745-749.
16. Cals L, Rixe O, Francois E et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 2004; 15: 1018-1024.
17. Souglakos J, Mavroudis D, Kakolyris S et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002; 20: 2651-2657.
18. Masi G, Allegrini G, Cupini S et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004; 15: 1766-1772.
19. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.